An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
Public ClinicalTrials.gov record NCT01633372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multiple Simon 2-Stage Study of Itacitinib Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
Study identification
- NCT ID
- NCT01633372
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 87 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2012 (Actual)
- Primary completion
- Dec 31, 2013 (Actual)
- Completion
- Jun 29, 2021 (Actual)
- Last update posted
- Aug 30, 2021
2012 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham Hematology Oncology Associates, LLC | Birmingham | Alabama | — | — |
| Mayo Clinic, Arizona | Scottsdale | Arizona | — | — |
| UCLA Hematology & Oncology | Los Angeles | California | — | — |
| Emory University | Atlanta | Georgia | — | — |
| St Agnes Hospital | Baltimore | Maryland | — | — |
| University of Michigan Cancer Center | Ann Arbor | Michigan | — | — |
| Mount Sinai School of Medicine | New York | New York | — | — |
| Oregon Health & Science University | Portland | Oregon | — | — |
| University of Pennsylvania Health System | Philadelphia | Pennsylvania | — | — |
| Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | — | — |
| South Carolina Oncology & Associates | Columbia | South Carolina | — | — |
| Boston Baskin Cancer Foundation, Inc. | Memphis | Tennessee | — | — |
| Tennessee Oncology | Nashville | Tennessee | — | — |
| MD Anderson Cancer Center | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01633372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2021 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01633372 live on ClinicalTrials.gov.